Literature DB >> 17442935

Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling.

Joseph P Sanderson1, Dean J Naisbitt, John Farrell, Charlotte A Ashby, M Jane Tucker, Michael J Rieder, Munir Pirmohamed, Stephen E Clarke, B Kevin Park.   

Abstract

Different signals in addition to the antigenic signal are required to initiate an immunological reaction. In the context of sulfamethoxazole allergy, the Ag is thought to be derived from its toxic nitroso metabolite, but little is known about the costimulatory signals, including those associated with dendritic cell maturation. In this study, we demonstrate increased CD40 expression, but not CD80, CD83, or CD86, with dendritic cell surfaces exposed to sulfamethoxazole (250-500 microM) and the protein-reactive metabolite nitroso sulfamethoxazole (1-10 microM). Increased CD40 expression was not associated with apoptosis or necrosis, or glutathione depletion. Covalently modified intracellular proteins were detected when sulfamethoxazole was incubated with dendritic cells. Importantly, the enzyme inhibitor 1-aminobenzotriazole prevented the increase in CD40 expression with sulfamethoxazole, but not with nitroso sulfamethoxazole or LPS. The enzymes CYP2C9, CYP2C8, and myeloperoxidase catalyzed the conversion of sulfamethoxazole to sulfamethoxazole hydroxylamine. Myeloperoxidase was expressed at high levels in dendritic cells. Nitroso sulfamethoxazole immunogenicity was inhibited in mice with a blocking anti-CD40L Ab. In addition, when a primary nitroso sulfamethoxazole-specific T cell response using drug-naive human cells was generated, the magnitude of the response was enhanced when cultures were exposed to a stimulatory anti-CD40 Ab. Finally, increased CD40 expression was 5-fold higher on nitroso sulfamethoxazole-treated dendritic cells from an HIV-positive allergic patient compared with volunteers. These data provide evidence of a link between localized metabolism, dendritic cell activation, and drug immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442935     DOI: 10.4049/jimmunol.178.9.5533

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Delayed drug hypersensitivity: models of T-cell stimulation.

Authors:  Jacqueline Adam; Werner J Pichler; Daniel Yerly
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 2.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 3.  Hypersensitivity reactions to HIV therapy.

Authors:  Mas Chaponda; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

4.  Modeling and insights into molecular basis of low molecular weight respiratory sensitizers.

Authors:  Xueyan Cui; Rui Yang; Siwen Li; Juan Liu; Qiuyun Wu; Xiao Li
Journal:  Mol Divers       Date:  2020-03-12       Impact factor: 2.943

5.  Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.

Authors:  James C Sacco; Lauren A Trepanier
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

6.  Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.

Authors:  Ayman Elsheikh; Sidonie N Lavergne; J Luis Castrejon; John Farrell; Haiyi Wang; Jean Sathish; Werner J Pichler; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

7.  "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells.

Authors:  S N Lavergne; H Wang; H E Callan; B K Park; D J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2009-08-07       Impact factor: 4.030

8.  Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.

Authors:  Sachin Bhusari; Mahmoud Abouraya; Marcia L Padilla; Marie E Pinkerton; Nicholas J Drescher; James C Sacco; Lauren A Trepanier
Journal:  Arch Toxicol       Date:  2010-03-11       Impact factor: 5.153

9.  Screening Trimethoprim Primary Metabolites for Covalent Binding to Albumin.

Authors:  Whitney M Nolte; Robert T Tessman; Jennifer L Goldman
Journal:  Med Chem Res       Date:  2020-06-04       Impact factor: 1.965

Review 10.  Managing the challenge of chemically reactive metabolites in drug development.

Authors:  B Kevin Park; Alan Boobis; Stephen Clarke; Chris E P Goldring; David Jones; J Gerry Kenna; Craig Lambert; Hugh G Laverty; Dean J Naisbitt; Sidney Nelson; Deborah A Nicoll-Griffith; R Scott Obach; Philip Routledge; Dennis A Smith; Donald J Tweedie; Nico Vermeulen; Dominic P Williams; Ian D Wilson; Thomas A Baillie
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.